Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation

European Journal of Haematology

Volumn 87, Issue 2, 2011, Pages 138-147

  Bieri, Sabine ^a   Roosnek, Eddy ^a   Ozsahin, Hulya ^a   Huguet, Saadia ^a   Ansari, Marc ^a   Trombetti, Andrea ^a   Helg, Claudine ^a   Chapuis, Bernard ^a   Miralbell, Raymond ^a   Passweg, Jakob ^a   Chalandon, Yves ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Late effects; Leukemia

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOGLOBULIN A ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CORTICOSTEROID THERAPY; DRUG MEGADOSE; EYE TOXICITY; FEMALE; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; HYPOTHYROIDISM; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; T CELL DEPLETION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; EYE DISEASES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPOTHYROIDISM; IMMUNOSUPPRESSION; INFECTION; LYMPHOCYTE DEPLETION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960386337     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01638.x     Document Type: Article

References (40)

1. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Morrow Transplant Registry. N Engl J Med 1999;341:14-21.
2. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from Bone Marrow Transplant Survivor Study. Blood 2007;10:3784-92.
3. Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF, Weiss M, Cohen A, Nekolla E, Kolb HJ. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997;126:184-92.
4. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5years after hematopoietic cell transplantation. J Clin Oncol 2010;28:1011-6.
5. Pond GR, Lipton JH, Messner HA. Long-term survival after blood and marrow transplantation: comparison with an age-and gender-matched normative population. Biol Blood Marrow Transplant 2006;12:422-9.
6. Bieri S, Roosnek E, Helg C, Verholen F, Robert D, Chapuis B, Passweg J, Miralbell R, Chalandon Y. Quality of life and social reintegration after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2008;42:819-27.
7. Abou-Mourad YR, Lau BC, Barnett MJ, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010;45:295-302.
8. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001;19:464-71.
9. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897-904.
10. Hasegawa W, Pond GR, Rifkind JT, Messner HA, Lau A, Daly AS, Kiss TL, Kotchetkova N, Galal A, Lipton JH. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005;35:51-5.
11. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999;131:738-44.
12. Landgren O, Gilbert ES, Rizzo DJ, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992-5001.
13. Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113:1175-83.
14. Bieri S, Helg C, Chapuis B, Miralbell R. Total-body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 2001;49:1071-7.
15. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, Keller A, Kurtz JM, Chapuis B. Renal toxicity after allogeneic bone marrow transplant: the combined effects of total body irradiation and graft-versus-host disease. J Clin Oncol 1996;14:579-85.
16. Miralbell R, Rouzaud M, Grob E, Nouet P, Bieri S, Majno SB, Botteron P, Montero M, Precoma JC. Can a total body irradiation technique be fast and reproducible? Int J Radiat Oncol Biol Phys 1994;29:1167-73.
17. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
18. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus leukemia reaction? A Prospective Phase II Study. Biol Blood Marrow Transplant 2006;12:102-10.
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
20. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-90.
21. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994;13:763-9.
22. Cornelissen JJ, van der Holt B, Petersen EJ, et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003;10:855-64.
23. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994;83:3090-6.
24. Tichelli A, Rovó A, Passweg J, Schwarze CP, Van Lint MT, Arat M, Socié G. Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009;2:583-60.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972;34:187-220.
27. Borklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, Ljungmann P. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 2007;40:1055-62.
28. Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 2004;104:1898-906.
29. Calissendorff BM, Lonnqvist B, el Azazi M. Cataract development in adult bone marrow transplant recipients. Acta Ophtalmol Scand 1995;73:152-4.
30. Gallardo D, Ferra C, Berlanga JJ, de la Banda E, Ponce C, Salar A, Alonso E, Espanñol I, Riu C, Grañena A. Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:1135-9.
31. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol 1997;97:865-70.
32. Socié G, Sélimi F, Sedel L, Frija J, Devergie A, Esperou Bourdeau H, Ribaud P, Gluckman E. Avascular necrosis of bone after bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol 1994;86:624-8.
33. Socie G, Tichelli A. Long-term care after stem-cell transplantation. Hematol J 2004;5(Suppl. 3):S39-43.
34. Sostak P, Padovan CS, Yousry TA, ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003;60:842-8.
35. Tauchmanovà L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, Rotoli B, Colao A. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for haematologic diseases. Cancer 2002;95:1076-84.
36. Thomas O, Mahé MA, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001;49:125-31.
37. Tichelli A, Duell T, Weiss M, Socié G, Ljungman P, Cohen A, van Lint M, Gratwohl A, Kolb HJ. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group for Blood and Marrow Transplantation (EBMT) Working party on late effects. Bone Marrow Transplant 1996;17:1105-1011.
38. Tichelli A, Gratwohl A, Egger T, Roth J, Prünte A, Nissen C, Speck B. Cataract formation after bone marrow transplantation. Ann Intern Med 1993;119:1175-80.
39. Torii Y, Hasegawa Y, Kubo T, Kodera Y, Minami S, Morishita Y, Yamada Y, Iwata H. Osteonecrosis of the femoral head after allogeneic bone marrow transplantation. Clin Orthop Relat Res 2001;382:124-32.
40. Zierhut D, Lohr F, Schraube P, Huber P, Wenz F, Haas R. Cataract incidence after total-body irradiation. Int J Radiat Oncol Biol Phys 2000;46:131-5.